Accepted Manuscript

A systematic analysis of VRC01 antibody expression in *Pichia pastoris* through signal peptide optimization

Rochelle Aw, Paul F. McKay, Robin J. Shattock, Karen M. Polizzi

PII: S1046-5928(17)30754-4
DOI: 10.1016/j.pep.2018.03.013
Reference: YPREP 5245

To appear in: *Protein Expression and Purification*

Received Date: 18 December 2017
Revised Date: 27 February 2018
Accepted Date: 26 March 2018

Please cite this article as: R. Aw, P.F. McKay, R.J. Shattock, K.M. Polizzi, A systematic analysis of VRC01 antibody expression in *Pichia pastoris* through signal peptide optimization, *Protein Expression and Purification* (2018), doi: 10.1016/j.pep.2018.03.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
A systematic analysis of VRC01 antibody expression in *Pichia pastoris* through signal peptide optimization

Rochelle Aw¹,², Paul F. McKay³, Robin J. Shattock³ and Karen M. Polizzi¹,²,*

¹Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK

²Centre for Synthetic Biology and Innovation, Imperial College London, SW7 2AZ, UK

³Department of Infectious Diseases, Imperial College London, London, W2 1PG, United Kingdom

*Corresponding Author

k.polizzi@imperial.ac.uk
Highlights

Production of VRC01 antibody in *Pichia pastoris* was increased 2-7 fold

Using the murine IgG1 signal peptide on the light chain results in higher yields

The use of bicistronic vectors did not increase the yield of VRC01

Abstract

*Pichia* (syn. *Komagataella*) *pastoris* has been used for recombinant protein production for over 30 years with over 5000 proteins reported to date. However, yields of antibody are generally low. We have evaluated the effect of secretion signal peptides on the production of a broadly neutralizing antibody (VRC01) to increase yield. Eleven different signal peptides, including the murine IgG1 signal peptide, were combinatorially evaluated for their effect on antibody titer. Strains using different combinations of signal peptides were identified that secreted approximately 2-7 fold higher levels of VRC01 than the previous best secretor, with the highest yield of 6.50 mg L\(^{-1}\) in shake flask expression. Interestingly it was determined that the highest yields were achieved when the murine IgG1 signal peptide was fused to the light chain, with several different signal peptides leading to high yield when fused to the heavy chain. Finally, we have evaluated the effect of using a 2A signal peptide to create a bicistronic vector in the attempt to reduce burden and increase transformation efficiency, but found it to give reduced yields compared to using two independent vectors.

Keywords (maximum of 6 keywords – American spelling)

*Pichia pastoris / Komagataella pastoris*

Broadly neutralizing antibody

VRC01

Signal peptide

2A sequence

Abbreviations
AA, α-amylase; α-MF, α-mating factor; AK, α-mating factor K; AKS, α-mating factor KS; AT, α-mating factor T; AOX1, alcohol oxidase 1; AP, alkaline phosphate; BMGY, buffered glycerol complex medium; BMMY, buffered methanol complex medium; bNAbs, broadly neutralizing antibodies; clonNAT, Nourseothricin; GA, glucoamylase; HEK, hamster embryonic kidney; IgG, Immunoglobulin G; IN, inulinase; IV, invertase; KP, killer protein; LZ, lysozyme; SA, serum albumin; YPD, yeast peptone dextrose
1. Introduction

The broadly neutralizing antibody (bNAb) VRC01 is currently undergoing Phase II clinical trials to determine its effectiveness in preventing HIV infection in high risk women and in men and transgender people who have sex with men [1, 2]. VRC01 works by binding to the gp120 envelope glycoprotein and blocking interaction with the CD4+ receptor; thus, preventing viral entry into the T-cell [3]. In vitro VRC01 has been shown to neutralize 91% of HIV isolates, and therefore is a promising candidate in the fight against HIV [4]. Results from two initial Phase I clinical trials indicate that VRC01 has been identified as a being able to delay the return of viral replication following interruption of antiretroviral therapy [5].

In most cases VRC01 is produced in hamster embryonic kidney (HEK) cells, although production in plants has also been reported [6]. Yields for plant production were up to 100 mg/kg in stably expressing lines. We have previously reported on the production of the bNAb VRC01 using Pichia (syn. Komagataella) pastoris, with yields up to 3.05 mg L\(^{-1}\) in shake flasks [7]. Our research utilized the murine IgG1 signal peptide (GWSCIILFLVATATGVHSQ) for the first time in P. pastoris, which outperformed the more popular α-mating factor from Saccharomyces cerevisiae [8, 9].

P. pastoris is often chosen as an expression host due to the high cell densities that can be achieved, up to 130 g L\(^{-1}\) dry cell weight, and therefore the corresponding high volumetric productivities [10]. P. pastoris secretes very few native proteins, thus purification can be made easier by directing recombinant proteins to the supernatant through the use of a signal peptide. There are many reported instances where the choice of signal peptides impacts the yields achieved for expression; for instance He et al. found that utilizing a bovine-casein signal peptide for the secretion of the xylanase xynB resulted in lower yields than using the α-mating factor (α-MF) pre-pro peptide from S. cerevisiae [11]. Gasser et al. were unable to secrete antibody fragments using a mAb leader signal peptide, but were able to secrete the same products using the α-MF [12]. Conversely the expression of bovine pancreatic trypsin inhibitor (BPTI) was unsuccessful when using the α-MF, but utilizing the human serum albumin (HSA) signal peptide resulted in successful secretion into the medium [13].
There are various truncations to the α-MF signal peptides that have been demonstrated to increase the cleavage efficiency of the STE13 protease for some proteins [14-16]. In addition, a series of other signal peptides have in various forms successfully resulted in the production of recombinant proteins; α-amylase [17], glucoamylase [18], inulinase [19] invertase [20], killer protein [19], lysozyme [21], and human serum albumin [13, 22]. As the optimal choice of signal peptides is often protein specific, testing different signal peptides should influence overall yield.

Another method to improve yield has been by using bicistronic vectors, which in the case of antibodies results in the production of both the heavy and the light chain from a single vector. These can be generated using internal ribosome entry sites (IRES) [23] or through the use of 2A peptide sequences [24]. Previously antibody fragments have been expressed using two expression cassettes in tandem; however, this requires two promoter and transcription terminator regions [12]. The IRES and 2A both utilise a single promoter, reducing the size of the vector and increasing transformation efficiency, as well as potentially reducing the impact of loop out recombination [25, 26]. IRES are large sequences and preferentially express the upstream protein at a 10-fold higher level of expression than the downstream protein, which explains their decreasing popularity [27]. The 2A sequence functions by causing a ribosome skip that cleaves between the terminal glycine and the beginning of the final protein resulting in two separate polypeptides [28-30]. 2A sequences have been used in P. pastoris for the production of complex multi-enzyme pathways [31] as well as for the production of antibodies [32]. The original 2A sequence was discovered in foot-and-mouth disease virus (FMDV), F2A, in 1991 [33]. In addition, there are the *Thosea asigna* virus sequence (T2A) and the porcine teschovirus-1 sequence (P2A) [24]. The P2A has been used for the production of antibodies in a streamlined system outlined by Shah et al. [32]. All three variants have been analysed in *P. pastoris* [31], and Geier et al. identified that using the F2A can result in production of the fusion protein as opposed to discrete protein. Furthermore, work carried out in mouse lines indicates expression of the second protein is higher when using the T2A compared to the P2A [34].

Here we set out to increase the production of the bNAb VRC01 by exploring a combinatorial library of signal peptides, including the murine signal peptide first
described in our previous paper. Furthermore, we evaluated the impact of using a 2A signal peptide to produce both chains of the antibody from a single bicistronic vector.

2. Materials and methods

2.1 Media and Growth Conditions

Bacterial strains were cultured in Lennox lysogeny broth (LB) medium (1% peptone au casein, 0.5% yeast extract, 0.5% NaCl) and supplemented with either 100 µg mL\(^{-1}\) Zeocin\(^\text{TM}\) (Life Technologies, Carlsbad, USA) or 100 µg mL\(^{-1}\) ampicillin (Sigma Aldrich, Dorset, UK). Yeast strains were cultured in YPD medium (2% peptone au casein, 1% yeast extract, 2% dextrose). Selection was carried out using Zeocin (Thermo Fisher Scientific, Paisley, UK) and Nourseothricin (clonNAT; Jena Bioscience, Jena, Germany) at 100 µg mL\(^{-1}\) each. Expression was carried out in buffered glycerol/methanol-complex medium (BMGY/BMMY; 1% yeast extract, 2% peptone, 100mM potassium phosphate, pH 6.0, 1.34% yeast nitrogen base, 4 x 10\(^{-5}\) % d-Biotin, 1% glycerol or 0.5% methanol).

2.2 Strain Construction

Bacterial recombinant DNA manipulation was carried out in Escherichia coli strain NEB 5-α (New England Biolabs, Hertfordshire, UK). The VRC01 heavy and light chains were previously cloned into either pPICZ\(\alpha\) or pJANs-1 [7]. Vectors containing 10 different signal peptides were purchased from ATUM\(^\text{SM}\) (Newark, California). The signal peptides include; α-amylase (AA), α-mating factor K (αK), α-mating factor KS (αKS), α-mating factor T (αT), glucoamylase (GA), insulinase (IN), invertase (IV), killer protein (KP), lysozyme (LZ) variant V11L and serum albumin (SA). The signal peptides were amplified using PCR and were cloned into either pPICZ\(\alpha\)-heavy or pJANs-light, replacing the α-mating factor using the Gibson DNA assembly method [35]. The PCR fragments were gel extracted using the Zymoclean\(^\text{TM}\) Gel DNA Recovery kit (Zymo Research Corporation, Irvine, USA). DNA was incubated at 50°C in equimolar concentrations of 100 ng of DNA with the ingredients of the Gibson master mix for an hour and 1 µL was transformed into NEB 5-α competent cells (New England Biolabs).

Pichia pastoris (syn. Komagataella pastoris) strain Δku70 (CBS 12694, CBS-KNAW, Fungal Biodiversity Centre, Utretcht, The Netherlands) was used as the background
strain. For cloning into *P. pastoris* 5-10 µg of plasmid DNA was linearized with Pmel
at a single restriction site within the *AOX1* promoter. The vectors were transformed
into cells by electroporation according to recommendations in the *Pichia Expression*
manual (Thermo Fisher Scientific) and grown for 3-5 days at 30°C on YPD medium
containing 100 µg mL⁻¹ Zeocin (Thermo Fisher Scientific) and 100 µg mL⁻¹
Nourseothricin (Jena Bioscience) to select for double transformants. For
nomenclature purposes the heavy chain will be denoted as (H) and light chain as (L)
following the signal peptide, i.e. αKH-GAL would be the combination of the α-mating
factor K signal peptide fused to the heavy chain and the glucoamylase signal peptide
fused to the light chain.

For the bicistronic vectors the T2A and light chain was amplified from r_αA-VRC01
and integrated into the pPICZ-heavy vector, in the orientation of light-T2A-heavy
[36]. After transformation into *P. pastoris* selection was carried out on YPD plates
containing 100 µg mL⁻¹ Zeocin (Thermo Fisher Scientific).

### 2.3 Copy number analysis

Genomic DNA was extracted using the DNeasy® Plant Mini Prep Kit (Qiagen,
Crawley, UK), quantified by Nanodrop™ (Thermo Fisher Scientific) and normalized
to 0.5 ng µL⁻¹ using distilled H₂O. Quantitative PCR was run on genomic DNA using
KICStart® SYBR® Green qPCR ReadyMix™ (Sigma Aldrich) in an Eppendorf
Mastercycler® ep realplex quantitative cycler (Eppendorf UK Ltd, Histon, UK). The
known 1 copy clone α-1 was used as a reference strain and all strains were
compared accordingly [7]. Data was analysed using the Pfaffl method, based on ∆∆-
Ct [37, 38] and normalized to *ACT1* as the housekeeping gene. Primers for the
heavy chain were AAT CAC AAG CCC AGC AAC AC and GGG CAT GTG TGT
TTG TCA C resulting in a 74 bp amplicon. Primers for the light chain were TGT CTT
CAT CTT CCC GCC ATC and ATT CAG CAG GCC ATC AAC AG resulting in a 70
bp amplicon. Primers for *ACT1* were GCT TTG TTC CAC CCA TCT GT and TGC
ATA CGC TCA GCA ATA CC resulting in a 163 bp amplicon. Cycling conditions
were 95°C for 5 minutes followed by 40 cycles of 95°C for 5 seconds, 58°C for 15
seconds and 72°C for 10 seconds with a melting curve afterwards to ensure a single
product was being measured. Error bars are representative of the Gaussian error
propagation of the standard deviation of $s_{\text{untreated control}}$, $s_{\text{treated control}}$, $s_{\text{untreated sample}}$ and $s_{\text{treated sample}}$ [39].

2.4 Protein Expression

Expression screening in *P. pastoris* was performed in 24 deep-well plates in 3 mL of medium and sealed with Breathe-Easy® sealing membrane (Sigma Aldrich). Larger scale expression in *P. pastoris* was performed in 250 mL glass baffled flasks in 25 mL of BMGY medium. Cells were incubated at 30°C, 216 rpm for 24 hours in BMGY to allow growth before being centrifuged at 4000 rpm for 5 minutes. The supernatant was removed and the medium replaced with BMMY to induce expression. Cultures were left to express at 20°C, 216 rpm for 72 hours before being harvested. Every 24 hours the culture was supplemented with 0.5% (v/v) methanol.

2.5 Western blot analysis

Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) was performed using 12% Tris-HCl SDS-PAGE gels. *P. pastoris* culture supernatants were denatured by boiling for 5 min in reducing SDS sample buffer (0.0625 M Tris–HCl, pH 6.8, 2.3% (w/v) SDS, 10% (w/v) glycerol and 0.01% Bromophenol blue, 5% (v/v) β-mercaptoethanol). To assess intracellular protein the *P. pastoris* pellet was treated as previously described [40]. Molecular weight was estimated by using a prestained protein ladder (10–170 kDa, Thermo Fisher Scientific). Transfer to an Immobilon®-FL PVDF membrane (Millpore (U.K) Ltd, Herfordshire, UK) was performed using a Novex® semi-dry blotter (Thermo Fisher Scientific). VRC01 antibody was detected by using a 1:5000 dilution of an AP-conjugated Rabbit Anti-Human IgG H&L (Abram, Cambridge, UK). Bands were developed using the alkaline phosphate substrate BCIP/NBT kit (Thermo Fisher Scientific).

2.6 Enzyme-Linked Immunosorbent assay (ELISA)

ELISA was performed on neat supernatant cultures from flask expression. For the total Ig ELISA, Nunc Maxisorp (Thermo Fisher Scientific) high-binding 96-well microplates were coated with 100 µL anti-human Kappa and Lambda light chain mix (Southern Biotech, Birmingham, US) in PBS at 4°C overnight. Wells were washed with 0.05% (v/v) Tween in PBS four times, and subsequently blocked with 200 µL 0.05% (v/v) Tween and 1% (v/v) Bovine Serum Albumin (BSA) in PBS (assay buffer)
for 1 hour at 37°C. To generate a standard curve 50 µL standard antibody in 5-fold serial dilution was added to triplicate wells, with a starting concentration of 1000 ng mL⁻¹. The plates were then incubated for 1 hour at 37°C, washed, and 100 µL detection antibody added (anti-human IgG HRP; Southern Biotech), diluted to 1:10,000 in assay buffer. After 1 hour incubation at 37°C wells were washed a further 4 times. 50 µL TMB (KPL Inc, Milford, USA) was added and incubated for 5 minutes. 50 µL of Stop solution (KPL Inc) was added and the absorbance measured at 450 nm immediately. Some ELISAs included a biotin amplification step where the detection antibody used was an anti-human IgG Biotin labelled (Southern Biotech), diluted to 1:10,000 in assay buffer, followed by a wash step and then incubation with a streptavidin-HRP conjugate (R&D Systems), diluted 1:200 in assay buffer, before washing and development of the signal with TMB as detailed above. To determine antigen-specific binding wells were coated with 50 µL CN54-gp140 antigen at 1 µg mL⁻¹ in PBS at 4°C in place of the IgG capture antibodies. The antibody concentration reported by the gp140 ELISA method is lower than that of the total antibody method due to different binding affinities to the plate bound antigen. Yields of VRC01 for shake flasks were recorded previously [7].

3. Results and discussion

3.1 Expression of VRC01 using the paired signal peptide

The signal peptides from the ATUM℠ expression library vectors were amplified and cloned into the existing pPICZ-heavy or pJAN-light vectors [7]. This created 20 vectors, containing the 10 signal peptides with either the light or heavy chains in addition to the original vectors containing the murine signal peptide (Figure 1). Of the new 10 vectors, each vector pair containing the same signal peptide (e.g. SAH and SAL) on the heavy and light chain was transformed in Δku70 with selection on both 100 µg mL⁻¹ Zeocin and 100 µg mL⁻¹ cloNAT. This background strain was chosen as it prevents off-target recombination, and as both vectors integrate into the same locus ensures correct integration [41]. The presence of both the heavy and light chain sequences was confirmed by colony PCR as previously described (data not shown) [7].

To control for clonal variation [42, 43], four colonies of each pair were expressed in microtiter plates and the expression was determined by ELISA (Figure 2) and
Western blot (Figure 3 and Supplementary Figure 1). From our original paper, the most highly expressed strain was M2, which in small scale produced 2.60 µg L⁻¹, which is represented on Figure 2 with the red line. None of the strains with new signal peptides outperformed this strain in small scale expression (Figure 2).

However, there was noticeable variation in expression of the heavy and light chains when culture supernatants were analyzed by Western blot, as indicated in the representative Western blots shown in Supplementary Figure 1. For example, using the GA signal peptide resulted in an abundance of light chain, but limited amounts of heavy chain, with most being retained in the pellet (Supplementary Figure 1). On the other hand, using the SA signal peptide resulted in higher levels of expression of the heavy chain than in GA, although there is still evidence that the heavy chain was not fully secreted (Supplementary Figure 1). The ratio of light to heavy chain is more balanced when using the SA signal peptide, and this is represented in the ELISA results (Figure 2) where there is increased signal using the SA signal peptide compared to the GA signal peptide.

Western blot heavy and light chain bands were measured by densitometry and calculated as a ratio to the previously published M2 strain (Figure 3). Light chains were highly secreted in strains with the αK, GA, IV, LZ and SA signal peptides, although IV shows proportionally higher levels of light chain maintained within the pellet than the other strains. Conversely the αKS, αT and KP signal peptides resulted in very low levels of light chain secretion, with the former two showing also very little retained within the pellet (Figure 3A). For the heavy chain, the AA, αK, LZ and SA signal peptides show the highest levels of secretion, although all show also antibody being retained within the pellet. Levels of antibody in strains using the αKS are low, but this could be due to the low levels of light chain production in these strains. αT shows higher levels of heavy chain in the supernatant than is retained in the pellet, and this implies that the low total antibody yield observed for this strain (Figure 2) is not as a result of the heavy chain being maintained within the pellet, but lower light chain expression, suggesting that this signal peptide is not compatible with high levels of production of VRC01.

3.2 Expression of VRC01 using combination signal peptides
The Western blot results (Figure 3 and Supplementary Figure 1) facilitated selection of signal peptides for study further. It is apparent that the choice of signal peptides affects the efficiency of secretion of heavy and light chains and therefore, using a combination of different signal peptides could increase yield. To select which signal peptides to explore in our combinatorial library, we used different criteria for the heavy and light chain. It has been shown that light chain can be secreted independently of the heavy chain, but not the other way around [12, 44, 45]. Therefore, signal peptides from strains that showed high levels of light chain in the supernatant where chosen for further strain construction irrespective of the secretion of the heavy chain. For the heavy chain, signal peptides were chosen based on either a high level of expression in the supernatant from the ELISA data (e.g. SA, LZ) or those that showed low levels of expression of the light chain and evidence of heavy chain accumulation in the cell pellet (e.g. AA, KP) since the antibody secretion in these strains could have been negatively impacted by low availability of the light chain. As a result, the following signal peptides were chosen to be fused with the heavy chain: AA, αK, αKS, IV, KP, LZ and SA. For the light chain the αK, GA, LZ and SA signal peptides were chosen. Furthermore, as the murine signal peptide resulted in the highest levels of secretion in our previous study, this was also used for both the heavy and the light chains. Therefore, we constructed a combinatorial library of 36 different sets of strains by transforming each combination of heavy and light chain vector into *P. pastoris*.

Four colonies from each combination were selected and antibody was expressed in microtiter plates as previously described. Antibody yield was analysed by ELISA (Figure 4) and Western blots (data not shown). Compared to the previously reported strain that used the murine secretion signal for both heavy and light chain (indicated by the red line), there were strains with higher yield, unlike when using identical signal peptides from the library for both the heavy and the light chains. Interestingly, the murine signal peptide appeared to be the best fusion partner for the light chain in all cases. As we have analysed multiple clones in order to account for clonal variation [42, 43] it was of note that all clones of AAH-ML, LH-ML and SAH-ML combination outperformed the M2 strain in small scale expression, suggesting that these signal peptides result in efficient processing of the antibody for secretion. The
best secreting clones of AAH-ML, LZH-ML and SAH-ML produced 1.5, 5 and 7 fold higher titers than M2 respectively.

The LZH-ML and SAH-ML strains had the highest antibody expression levels overall. Therefore, we scaled up expression of these strains to shake flasks and compared the titers of total and gp140 specific antibody to those from M2 (Figure 5). Despite the small scale expression results, not all of the clones outcompete M2 in antibody yield in shake flask expression. It has been reported previously that reproducible scale up is difficult to achieve in *P. pastoris*, often due to the high oxygen levels required, which can result in cell death [46]. Nonetheless compared to M2, two clones of each of the strains produced higher total and gp140 specific antibody concentrations (LZHML1, LZHML4, SAHML2 and SAHML4).

To understand if the differences in titer from different strains were a result of differences in gene copy number [43], we analysed the copy number of the four LZHML and SAHML strains. We had previously determined that the M2 strain has two copies of both the heavy and the light chain. Interestingly, the lower expressing clones of LZHML and SAHML had higher copy numbers, ranging from 4 to 8 copies of the heavy chain and 3 to 6 copies of the light chain (Supplementary Figure 2). This is consistent with previous findings that implied the benefits of increasing gene dosage plateau at a maximum value where secretion saturation can occur, resulting in detrimental effects on yield on further increase in copy number [26]. In fact, there was a negative correlation between the number of heavy chain copies and the level of expression (r=0.715), which was less pronounced for the light chain correlation (r=0.5951). This is supported by the findings that the heavy chain cannot be secreted without the light chain; therefore the heavy chain remains the limiting factor for the concentration of intact antibody [12, 44, 45].

From the best secreting strains LZHML1, SAHML2 and SAHML4 had one copy of heavy chain and two copies of light chain whilst LZHML4 had two copies of each the heavy and the light chains (comparable to the M2 strain analysed). This indicates that the variation observed between the levels of expression using different signal peptides is not due to differences in copy number, but results from the different signal peptides.
Whilst there is no significant difference when comparing all of the strains, SAHML4 had a total expression of 6.5 mg L\(^{-1}\) and 187 µg L\(^{-1}\) of gp140 specific antibody. This is a 2.13 and 1.77 fold increase respectively compared to M2, which was the highest secretor found from our previous experiments.

### 3.3 Expression of VRC01 using the T2A signal peptide

A recent investigation into creating an automated pipeline for the production of HIV-specific monoclonal antibodies in *P. pastoris* utilized a 2A peptide sequence to generate a single vector to express both the heavy and the light chains [32]. We decided to generate bicistronic vectors for the MHML, LZHML and SAHML combinations as these gave the highest yields when utilising separate plasmids. As the T2A sequence from *Thosea asigna* virus was shown to produce discrete proteins in a previous investigation and results in higher expression of the second protein, this peptide sequence was used as a linker between the light and heavy chains [31, 34]. A single bicistronic vector should reduce the burden on *P. pastoris* and increase transformation efficiency [25, 47]. It has previously been demonstrated that an excess of light chain can promote folding and increase antibody stability; therefore the light chain was placed upstream of the T2A signal peptide [32, 48].

Initially, twenty clones from each of the transformations were expressed in microtiter plates and the yield observed via dot blot (data not shown). From the dot blots results, we selected four of the highest expressing clones, which were expressed in shake flasks for 72 hours in the methanol containing medium BMMY (Figure 6). Despite the reduced burden, no clones showed higher expression than the M2 strain originally described. The MLT2AMH strains had a mean total antibody expression of 958 µg L\(^{-1}\) and a mean of 36.8 µg L\(^{-1}\) of gp140 specific antibody, both over a third lower than the M2 strain with the same signal peptides. The highest yield came from the MLT2SAH strains; however, the mean expression was still lower at 1.7 mg L\(^{-1}\) and 38.2 µg L\(^{-1}\) for total antibody and gp140 specific antibody concentrations respectively. The highest individual expressing strain was MLT2ASAH1 at 2.9 mg L\(^{-1}\) of total antibody, although for gp140 specific antibody this was MLT2ASAH4 at 77.7 µg L\(^{-1}\). We previously reported that the signal from the gp140-specific ELISA was between 4-5% that of the total antibody ELISA for antibody expressed in mammalian 293T cells as well as *P. pastoris* [7]. However, here we see variations in this
percentage depending on the signal peptide used, with ranges between 1.76% and 4.3%. Since some strains show percentages in the same range as our previous measurements, this disparity is unlikely to be due to incomplete processing of the 2A sequence and is perhaps more likely to be signal peptide related (Supplementary Figure 3).

It would appear from our findings that the use of a peptide cleavage signal was not effective for increasing the expression of the VRC01 antibody. Further investigations are required to determine if this is specific for T2A or whether other 2A peptides may result in higher yields, or whether the heavy chain upstream of the light chain results in increased production.

4. Conclusions

Through the combinatorial exploration of signal peptides, we have increased the expression of the bNAb VRC01 in *P. pastoris* by 2-7 fold with yields of up to 6.5 mg L\(^{-1}\) in shake flask expression. This was through the combination of different signal peptides on both the heavy and the light chain. We have determined that the use of the murine IgG1 signal peptide resulted in the highest yields when fused to the light chain, with greater flexibility on the signal peptide for the heavy chain. Surprisingly the use of the T2A peptide sequence resulted in lower yields than when using independent plasmids. Further investigations into the choice of a cleavage sequence would be required to determine whether this is the most efficient approach for antibody production in *P. pastoris*.

Declarations of interest

None

Author contributions

RA designed and performed the experiments and helped draft the manuscript. PM performed the ELISA experiments and analysis. RS, PM and KP helped design the experiments and draft the manuscript. RS and KP conceived the study. All authors read and approved the final manuscript.

Acknowledgments
The authors would like to thank the Wellcome Trust for an Institutional Strategic Support Fund Network of Excellence Award and the EPSRC Frontiers Engineering Programme (EP/K038648/1) for funding. All of the data underpinning this study are contained within the manuscript and can be used without restriction.

References

1. NIAID Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2017/11/20]. Available from: https://clinicaltrials.gov/ct2/show/NCT02568215. NLM Identifier: NCT02568215

2. NIAID Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2016/07/11]. Available from: https://clinicaltrials.gov/ct2/show/NCT02716675. NLM Identifier: NCT02716675

3. Li, Y., S. O’Dell, L.M. Walker, et al., Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol, 2011. 85(17): p. 8954-67.

4. Wu, X., Z.Y. Yang, Y. Li, et al., Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 2010. 329(5993): p. 856-61.

5. Bar, K.J., M.C. Sneller, L.J. Harrison, et al., Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption. N Engl J Med, 2016. 375(21): p. 2037-2050.

6. Teh, A.Y., D. Maresch, K. Klein, et al., Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol J, 2014. 12(3): p. 300-11.

7. Aw, R., P.F. McKay, R.J. Shattock, et al., Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris. AMB Express, 2017. 7(1): p. 70.

8. Kabanova, A., L. Perez, D. Lilleri, et al., Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies. Proceedings of the National Academy of Sciences, 2014. 111(50): p. 17965-17970.

9. Zuo, Z., X. Jimenez, L. Witte, et al., An efficient route to the production of an IgG-like bispecific antibody. Protein Engineering, 2000. 13(5): p. 361-367.

10. Ahmad, M., M. Hirz, H. Pichler, et al., Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol, 2014. 98(12): p. 5301-17.

11. He, Z., Y. Huang, Y. Qin, et al., Comparison of alpha-factor preprosequence and a classical mammalian signal peptide for secretion of recombinant xylanase xynB from yeast Pichia pastoris. J Microbiol Biotechnol, 2012. 22(4): p. 479-83.
12. Gasser, B., M. Maurer, J. Gach, et al., *Engineering of Pichia pastoris for improved production of antibody fragments*. Biotechnol Bioeng, 2006. **94**(2): p. 353-61.

13. Yang, L., W. Dong, J. He, et al., *Expression and purification of natural N-terminal recombinant bovine pancreatic trypsin inhibitor from Pichia pastoris*. Biol Pharm Bull, 2008. **31**(9): p. 1680-5.

14. Brake, A., J. Merryweather, D. Coit, et al., *Alpha-factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae*. Proc Natl Acad of Sci USA, 1984. **81**: p. 4642 - 4646.

15. Cabral, K.M., M.S. Almeida, A.P. Valente, et al., *Production of the active antifungal Pism sativum defensin 1 (Psd1) in Pichia pastoris: overcoming the inefficiency of the STE13 protease*. Protein Expr Purif, 2003. **31**(1): p. 115-22.

16. Micheelsen, P.O., P.R. Østergaard, L. Lange, et al., *High-level expression of the native barley α-amylose/subtilisin inhibitor in Pichia pastoris*. Journal of Biotechnology, 2008. **133**(4): p. 424-432.

17. Liu, S.-H., W.-I. Chou, C.-C. Sheu, et al., *Improved secretory production of glucoamylase in Pichia pastoris by combination of genetic manipulations*. Biochemical and Biophysical Research Communications, 2005. **326**(4): p. 817-824.

18. Whittaker, M.M. and J.W. Whittaker, *Expression of recombinant galactose oxidase by Pichia pastoris*. Protein Expr Purif, 2000. **20**(1): p. 105-11.

19. Choi, B.K., J.K. Actor, S. Rios, et al., *Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response*. Glycoconj J, 2008. **25**(6): p. 581-93.

20. Valdes, I., L. Hermida, A. Zulueta, et al., *Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein*. Mol Biotechnol, 2007. **35**(1): p. 23-30.

21. Oka, C., M. Tanaka, M. Muraki, et al., *Human lysozyme secretion increased by alpha-factor pro-sequence in Pichia pastoris*. Bioscience, biotechnology, and biochemistry, 1999. **63**(11): p. 1977-1983.

22. Xiong, R. and J. Chen, *Secreted expression of human lysozyme in the yeast Pichia pastoris under the direction of the signal peptide from human serum albumin*. Biotechnol Appl Biochem, 2008. **51**(Pt 3): p. 129-34.

23. Liang, S., Y. Lin, C. Li, et al., *Internal ribosome entry site mediates protein synthesis in yeast Pichia pastoris*. Biotechnol Lett, 2012.

24. Szymczak, A.L., C.J. Workman, Y. Wang, et al., *Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector*. Nat Biotechnol, 2004. **22**(5): p. 589-94.

25. Lin-Cereghino, J., M.D. Hashimoto, A. Moy, et al., *Direct selection of Pichia pastoris expression strains using new G418 resistance vectors*. Yeast, 2008. **25**(4): p. 293-9.

26. Aw, R. and K.M. Polizzi, *Can too many copies spoil the broth?* Microb Cell Fact, 2013. **12**: p. 128.

27. Mizuguchi, H., Z. Xu, A. Ishii-Watabe, et al., *IRES-Dependent Second Gene Expression Is Significantly Lower Than Cap-Dependent First Gene Expression in a Bicistronic Vector*. Molecular Therapy. **1**(4): p. 376-382.

28. de Felipe, P., G.A. Luke, L.E. Hughes, et al., *E unum pluribus: multiple proteins from a self-processing polyprotein*. Trends Biotechnol, 2006. **24**(2): p. 68-75.
29. Donnelly, M.L., G. Luke, A. Mehrotra, et al., Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol, 2001. 82(Pt 5): p. 1013-25.

30. Trichas, G., J. Begbie, and S. Srinivas, Use of the viral 2A peptide for bicistronic expression in transgenic mice. BMC Biology, 2008. 6: p. 40-40.

31. Geier, M., P. Fauland, T. Vogl, et al., Compact multi-enzyme pathways in P. pastoris. Chemical Communications, 2015. 51(9): p. 1643-1646.

32. Shah, K.A., J.J. Clark, B.A. Goods, et al., Automated pipeline for rapid production & screening of HIV-specific monoclonal antibodies using Pichia pastoris. Biotechnol Bioeng, 2015.

33. Ryan, M.D., A.M. King, and G.P. Thomas, Cleavage of foot-and-mouth disease virus polyprotein is mediated by residues located within a 19 amino acid sequence. J Gen Virol, 1991. 72 (Pt 11): p. 2727-32.

34. Liu, Z., O. Chen, J.B.J. Wall, et al., Systematic comparison of 2A peptides for cloning multi-genes in a polycistronic vector. Scientific Reports, 2017. 7: p. 2193.

35. Gibson, D.G., L. Young, R.Y. Chuang, et al., Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods, 2009. 6(5): p. 343-5.

36. Royle, K.E. and K. Polizzi, A streamlined cloning workflow minimising the time-to-strain pipeline for Pichia pastoris. Sci Rep, 2017. 7(1): p. 15817.

37. Pfaffl, M.W., A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 2001. 29(9): p. e45.

38. Livak, K.J. and T.D. Schmittgen, Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method. Methods, 2001. 25(4): p. 402-408.

39. Yuan, J.S., A. Reed, F. Chen, et al., Statistical analysis of real-time PCR data. BMC Bioinformatics, 2006. 7: p. 85-85.

40. Kushnirov, V.V., Rapid and reliable protein extraction from yeast. Yeast, 2000. 16(9): p. 857-860.

41. Naatsaari, L., B. Mistlberger, C. Ruth, et al., Deletion of the Pichia pastoris KU70 Homologue Facilitates Platform Strain Generation for Gene Expression and Synthetic Biology. PLoS ONE, 2012. 7(6): p. e39720.

42. Aw, R., G.R. Barton, and D.J. Leak, Insights into the prevalence and underlying causes of clonal variation through transcriptomic analysis in Pichia pastoris. Appl Microbiol Biotechnol, 2017. 101(12): p. 5045-5058.

43. Schwarzhans, J.P., D. Wibberg, A. Winkler, et al., Integration event induced changes in recombinant protein productivity in Pichia pastoris discovered by whole genome sequencing and derived vector optimization. Microb Cell Fact, 2016. 15(1): p. 84.

44. Lee, Y.K., J.W. Brewer, R. Hellman, et al., BiP and immunoglobulin light chain cooperate to control the folding of heavy chain and ensure the fidelity of immunoglobulin assembly. Mol Biol Cell, 1999. 10(7): p. 2209-19.

45. Gach, J., M. Maurer, R. Hahn, et al., High level expression of a promising anti-idiotypic antibody fragment vaccine against HIV-1 in Pichia pastoris. J Biotechnol, 2007. 128(4): p. 735 - 746.

46. Weis, R., R. Luiten, W. Skranc, et al., Reliable high-throughput screening with Pichia pastoris by limiting yeast cell death phenomena. FEMS Yeast Res, 2004. 5(2): p. 179-89.
47. Zhu, T., M. Guo, C. Sun, et al., A systematical investigation on the genetic stability of multi-copy Pichia pastoris strains. Biotechnology Letters, 2009. 31(5): p. 679-684.

48. Schlatter, S., S.H. Stansfield, D.M. Dinnis, et al., On the optimal ratio of heavy to light chain genes for efficient recombinant antibody production by CHO cells. Biotechnol Prog, 2005. 21(1): p. 122-33.

**Figure 1.** Graphical representation of vectors. Twenty vectors were generated containing a different signal peptide combined with the light or the heavy chain.

**Figure 2.** Concentration of total antibody by ELISA. Antibody concentrations were calculated of total IgG1 antibody. Four clones of each condition were expressed for 72 hours in BMMY and are represented in box plot format. The red line indicates the highest yield achieved from M2 [7] at 2.60 µg L⁻¹.

**Figure 3.** Relative expression of heavy and light chains compared to M2. From Western blots the densitometry of bands was calculated in relation to secreted M2 heavy and light chain. Ratios of both the supernatant and the pellet were calculated and plotted on the same graph. Box plots are representative of four clones from each signal peptide. **A)** Light chain **B)** Heavy chain.

**Figure 4.** Concentration of total antibody by ELISA for combination strains. Antibody concentrations were calculated of total IgG1 antibody by ELISA. Four clones of each condition were expressed for 72 hours in BMMY and are represented in box plot format. The red line indicates the highest yield achieved from M2 [7] at 2.60 µg L⁻¹.

**Figure 5.** Concentration of total and gp140 specific antibody from large scale expression of LZHML and SAHML. Antibody concentrations were calculated for total IgG1 and gp140 specific antibody. Samples were expressed in BMMY for 72 hours in 25 mL cultures. M2 is representative of previous results reported from large scale expression [7].

**Figure 6.** Concentration of total and gp140 specific antibody of MLT2ALZH, MLT2SAH and MLT2AMH. Antibody concentrations were calculated of total IgG1 and gp140 specific antibody. Samples were expressed in BMMY for 72 hours in 25 mL cultures. M is representative of previous results reported from large scale
expression [7]. **A)** Total antibody concentration. **B)** gp140 specific antibody concentration.

**Supplementary Figure 1. Western blot of GA and SA strains.** Representative Western blots indicating heavy and light chains. Samples were run on a denaturing gel, using a secondary rabbit anti-human IgG heavy and light antibody. **A)** glucoamylase (GA); **B)** serum albumin (SA).

**Supplementary Figure 2. Copy number of heavy and light chains of LZHML and SAHML.** Copy number was determined by qPCR using the Pfaffl method against a known one copy clone. Error bars are calculated using the Gaussian error propagation of the standard deviation of s[untreated control], s[treated control], s[untreated sample] and s[treated sample].

**Supplementary Figure 3. Western blot of T2A bicistronic strains.** Expression from large scale cultures were run on a denaturing gel, using a secondary rabbit anti-human IgG heavy and light antibody. **L)** Ladder, 1) MLT2AMH-1, 2) MLT2AMH-2, 3) MLT2AMH-3, 4) MLT2AMLH-4, 5) MLT2ALZH-1, 6) MLT2ALZH-2, 7) MLT2ALZH-3, 8) MLT2ALZH-4, 9) MLT2ASAH-1, 10) MLT2ASAH-2, 11) MLT2ASAH-3, 12) MLT2ASAH-4, 13) M2.
AOX1p

Resistance Marker

AOX1 TT

SV40 polyA

VRC01 Chain
- Light chain
- Heavy chain

Secretion signal
- α-amylase (AA)
- α-MF (K) (αK)
- α-MF (KS) (αKS)
- α-MF (T) (αT)
- Glucoamylase (GA)
- Insulinase (IN)
- Invertase (IV)
- Killer protein (KP)
- Lysozyme (LZ)
- Serum albumin (SA)
A

Fold change to M2

Superantant Pellet

AA  AK  AKS  AT  GA  IN  IV  KP  LZ  SA

B

Fold change to M2

Superantant Pellet

AA  AK  AKS  AT  GA  IN  IV  KP  LZ  SA
Total antibody concentration (µg L⁻¹) vs. gp140 antibody concentration (ng mL⁻¹). The graph shows the concentration of total antibodies and gp140 antibodies for different samples labeled as LZHML1, LZHML2, LZHML3, LZHML4, SAHML1, SAHML2, SAHML3, SAHML4, and M2.
Highlights

Production of VRC01 antibody in *Pichia pastoris* was increased 2-7 fold

Using the murine IgG1 signal peptide on the light chain results in higher yields

The use of bicistronic vectors did not increase the yield of VRC01